483
Ann R. Woodbridge, M.D.FDA 483 - Ann R. Woodbridge, M.D. - January 24, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Ann R. Woodbridge, M.D., a clinical investigator in Dallas, TX, revealed a significant deviation from the investigational plan. The firm failed to ensure timely submission of bone mineral density scans, leading to delays in identifying and discontinuing subjects who met withdrawal criteria from a study. This indicates a failure to adhere to study protocols and ensure subject safety and data integrity.
Open in Dashboard
ID · 327fdeb4-c1e0-49a0-a236-246abfb98c61